Collegium Pharmaceutical
COLL
101 hedge funds and large institutions have $526M invested in Collegium Pharmaceutical in 2017 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 39 increasing their positions, 14 reducing their positions, and 7 closing their positions.
371% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 7
179% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 14
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
92% more capital invested
Capital invested by funds: $274M → $526M (+$252M)
35% more funds holding
Funds holding: 75 → 101 (+26)
0.93% less ownership
Funds ownership: 88.46% → 87.53% (-0.93%)
53% less call options, than puts
Call options by funds: $622K | Put options by funds: $1.34M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$47.2M |
| 2 |
First Manhattan
New York
|
+$6.68M |
| 3 |
SPPAM
Summit Partners Public Asset Management
Boston,
Massachusetts
|
+$6.59M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$6.34M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$4.99M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Cadian Capital Management
New York
|
-$21.6M |
| 2 |
Millennium Management
New York
|
-$15.8M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$10.3M |
| 4 |
JGC
J. Goldman & Co
New York
|
-$5.48M |
| 5 |
BCMNY
Buckingham Capital Management (New York)
New York
|
-$5.39M |
COLL Hedge Fund Activity: Q4 2017 in Review
101 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Collegium Pharmaceutical (COLL) for Q4 2017, worth a combined $526M — up 92% from $274M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new COLL positions and 7 closed out — a net gain of 26 holders — while 39 added to existing stakes and 14 trimmed.
The largest buyer was Janus Henderson Group, opening a new position worth an estimated $47.2M. The largest seller was Cadian Capital Management, exiting entirely with an estimated $21.6M sold.
- 101 institutional investors held Collegium Pharmaceutical (COLL) as of Q4 2017, up from 75 in Q3 2017.
- Funds reported $526M of Collegium Pharmaceutical stock for Q4 2017, up 92% quarter-over-quarter.
- 33 funds opened new Collegium Pharmaceutical positions in Q4 2017 and 7 closed out, a net change of +26 holders.
- The largest Collegium Pharmaceutical buyer in Q4 2017 was Janus Henderson Group, an estimated $47.2M added.
- The largest Collegium Pharmaceutical seller in Q4 2017 was Cadian Capital Management, an estimated $21.6M sold.
Based on aggregated 13F filings for Q4 2017.